Publications by authors named "Kevin Biglan"

Claim this Profile
B
Biomarkers.
Kay Hoong Chow, Tongrong Wang, Ilke Tunali, Samantha C Burnham, Sergey Shcherbinin, Kevin Biglan

Alzheimers Dement· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stable two-year longitudinal clinical outcomes in LRRK2 G2019S non-manifest carriers in a remote nationwide study.
William Barbosa, Peggy Auinger, Meghan Pawlik, Emily Hartman, Saloni Sharma, Kevin Biglan

Parkinsonism Relat Disord· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving Prediction of Falls and Cognitive Impairment in Parkinson Disease: Protocol for a Decentralized Observational Study.
Audrey Hoyt, Casey Dorney, Peggy Auinger, Kathryn Murphy, Michelle Porto, Kevin Biglan

JMIR Res Protoc· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Using Clinical Scales and Digital Measures to Explore Falls in Patients with Lewy Body Dementia.
Chakib Battioui, Albert Man, Melissa Pugh, Jian Wang, Xiangnan Dang, Kevin Biglan

Digit Biomark· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Wrist-worn sensor-based measurements for drug effect detection with small samples in people with Lewy Body Dementia.
Chen Chen, Nathan R Kowahl, Erin Rainaldi, Maximilien Burq, Leanne M Munsie, Kevin Biglan

Parkinsonism Relat Disord· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease Progression and Longitudinal Clinical Outcomes of Lewy Body Dementia in the NACC Database.
Julie Chandler, Mihaela Georgieva, Urvi Desai, Noam Kirson, Henry Lane, Kevin Biglan

Neurol Ther· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Remote Longitudinal Observational Study of Individuals at Genetic Risk for Parkinson Disease: Baseline Results.
Stella Jensen-Roberts, Taylor L Myers, Peggy Auinger, Paul Cannon, Helen M Rowbotham, Kevin Biglan

Neurol Genet· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the Use of Digital Biomarkers to Test Treatment Effects on Cognition and Movement in Patients with Lewy Body Dementia.
Jian Wang, Chakib Battioui, Andrew McCarthy, Xiangnan Dang, Hui Zhang, Kevin Biglan

J Parkinsons Dis· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epidemiology and economic burden of Lewy body dementia in the United States.
Urvi Desai, Julie Chandler, Noam Kirson, Mihaela Georgieva, Hoi Ching Cheung, Kevin Biglan

Curr Med Res Opin· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor-Positive Allosteric Modulator, in Patients With Parkinson Disease.
Darren Wilbraham, Kevin M Biglan, Kjell A Svensson, Max Tsai, Melissa Pugh

Clin Pharmacol Drug Dev· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Mevidalen in Lewy Body Dementia: A Phase 2, Randomized, Placebo-Controlled Trial.
Kevin Biglan, Leanne Munsie, Kjell A Svensson, Paul Ardayfio, Melissa Pugh

Mov Disord· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Dopamine D1 Receptor Positive Allosteric Modulator Mevidalen (LY3154207) Enhances Wakefulness in the Humanized D1 Mouse and in Sleep-Deprived Healthy Male Volunteers.
Andrew P McCarthy, Kjell A Svensson, Elaine Shanks, Claire Brittain, Brian J Eastwood, Kevin M Biglan

J Pharmacol Exp Ther· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics of Parkinson's Disease in Patients with and without Cognitive Impairment.
Julie M Chandler, Radhika Nair, Kevin Biglan, Erin A Ferries, Leanne M Munsie

J Parkinsons Dis· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Virtual Cohort Study of Individuals at Genetic Risk for Parkinson's Disease: Study Protocol and Design.
Ruth B Schneider, Taylor L Myers, Helen M Rowbotham, Marie K Luff, Katherine Amodeo, Kevin Biglan

J Parkinsons Dis· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lewy Body Dementia Association's Industry Advisory Council: proceedings of the second annual meeting.
Jennifer G Goldman, Bradley F Boeve, Melissa J Armstrong, Doug R Galasko, James E Galvin, Kevin Biglan

Alzheimers Res Ther· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor-Positive Allosteric Modulator (D1PAM), in Healthy Subjects.
Darren Wilbraham, Kevin M Biglan, Kjell A Svensson, Max Tsai, William Kielbasa

Clin Pharmacol Drug Dev· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of a virtual longitudinal observational study in Parkinson's disease (AT-HOME PD).
Ruth B Schneider, Larsson Omberg, Eric A Macklin, Margaret Daeschler, Lauren Bataille, Kevin Biglan

Ann Clin Transl Neurol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility, Reliability, and Value of Remote Video-Based Trial Visits in Parkinson's Disease.
Christopher G Tarolli, Kelly Andrzejewski, Grace A Zimmerman, Michael Bull, Steven Goldenthal, Kevin Biglan

J Parkinsons Dis· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials.
Jennifer G Goldman, Leah K Forsberg, Bradley F Boeve, Melissa J Armstrong, David J Irwin, Kevin Biglan

Alzheimers Res Ther· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Video research visits for atypical parkinsonian syndromes among Fox Trial Finder participants.
Christopher G Tarolli, Grace A Zimmerman, Steven Goldenthal, Blake Feldman, Sarah Berk, Kevin M Biglan

Neurol Clin Pract· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations.
Claire Brittain, Andrew McCarthy, Michael C Irizarry, Dana McDermott, Kevin Biglan

Parkinsonism Relat Disord· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Earlier Dopaminergic Treatment in Parkinson's Disease Is Not Associated With Improved Outcomes.
Ruth B Schneider, Xiang Lu, Kevin Biglan, Michael P McDermott

Mov Disord Clin Pract· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Telemedicine for Parkinson's Disease: Limited Engagement Between Local Clinicians and Remote Specialists.
Molly J Elson, E Anna Stevenson, Blake A Feldman, Jihoon Lim, Christopher A Beck, Kevin M Biglan

Telemed J E Health· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis